Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
WALTHAM, Mass., Sept. 07, 2017 -- Radius Health, Inc. (Nasdaq:RDUS), a fully integrated science-driven biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that Jesper Høiland, President and CEO of Radius, will participate in a fireside chat at the Morgan Stanley 15th Annual Global Healthcare Conference in New York on Wednesday, September 13, 2017 at 10:30 a.m. Eastern Time.
A live webcast of the presentation will be available by visiting the Investors section of Radius' website at http://ir.radiuspharm.com/events.cfm. A replay of the webcast will be archived on Radius' website for 30 days following the presentation.
About Radius
Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product, TYMLOS (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius clinical pipeline includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius' RAD140, a non-steroidal, selective androgen receptor modulator (SARM), is under investigation for potential use in hormone receptor positive breast cancer. For more information, please visit www.radiuspharm.com.
Investor Relations Contact: Barbara Ryan Email: [email protected] Phone: 203-274-2825
